<DOC>
	<DOCNO>NCT01188109</DOCNO>
	<brief_summary>The purpose study investigate investigator use specific marker pancreatic tumor determine patient benefit receive combination chemotherapy gemcitabine cisplatin undergoing resection pancreatic cancer . The investigator also investigate benefit receive chemotherapy drug oppose gemcitabine undergo complete resection tumor .</brief_summary>
	<brief_title>Gemcitabine/Cisplatin Resected Pancreas Cancer : Establishing Role ERCC1 Treatment Decision</brief_title>
	<detailed_description>The study specifically look ERCC1 expression pancreas cancer regard prognostic predictive value biomarker patient receive Gem / Cis adjuvant therapy resection .</detailed_description>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Pancrelipase</mesh_term>
	<criteria>1 . Adults ( ≥ 18 year ) time sign informed consent form 2 . Understand voluntarily sign informed consent form 3 . Able adhere study visit schedule protocol requirement 4 . Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 5 . Absolute neutrophil count ≥ 1500 / mm³ 6 . Platelet count ≥ 100,000 / mm³ 7 . Resectable pancreatic adenocarcinoma 8 . Pathologic diagnosis pancreatic adenocarcinoma 1 . Any serious medical condition , laboratory abnormality , psychiatric illness would prevent subject signing informed consent form 2 . A history renal dysfunction ( serum creatinine &gt; 1.8 mg/dL ) 3 . Presence active infection 4 . Untreated second malignancy 5 . Pregnant breast feeding female ( A urine pregnancy test obtain woman childbearing age initial screen prior study enrollment administration chemotherapy . )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Pancreatic Neoplasms</keyword>
	<keyword>Pancreatic cancer</keyword>
</DOC>